22 research outputs found
Supporting the Negotiated Selection of a Pareto Optimal Solution: A design study on the added value of a decision aiding approach with Simulation-Based Many-Objective Optimisation
No full textFrom a content perspective, Simulation-Based Many-Objective Optimisation with a posteriori decision analysis is a promising method in analysing and solving semi- structured process improvement problems. From a process management perspective, the use of MOO can be perceived dicult; the optimisation process requires a structured problem formulation and the output of the optimisation can cause information overload for the decision makers. This paper presents a decision aiding approach with Simulation-Based Many Objective Optimisation to demonstrate that these burdens can be overcome and that the approach can be not only of added value for the content of the decision making, but also has a strategic role in the decision making process. The decision aiding approach can lead to (1) increased trust in the optimisation results, (2) more awareness about the preferences of other stakeholders, (3) faster convergence of the preferences of the decision makers and thus more progress in the decision making process and (4) increased support for the selected solution. Future research can focus on the application of the decision aiding approach to ill-structured problems where decision makers from different organisations are involved.Technology, Policy and ManagementPolicy AnalysisSystems Engineering, Policy Analysis & Management (SEPAM
Surgical care of incarcerated patients: Doing the right thing, explicit bias, and ethics
No full text“The surgeon doesn’t know how much power they have at that moment, you know, and I think that they should use their power instead of being intimidated by [prison officers].”
There are 2.3 million people in jail or prison in the United States - more than any other country in the world; 10.6 million people cycle through jails annually, with approximately 750,000 held in jail on any given day. With such a large number of incarcerated people, we suspect that most surgeons have cared for incarcerated patients and will continue to do so. In this article, we will discuss this care and the ethical principles that have guided it for the past 50 years
Financing fire protection for timber lands under Oregon laws
No full textby W.H. Dreesen.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may not be suitable for legal purposes.Includes bibliographical references.Mode of access: Internet from the Oregon Government Publications Collection.Text in English
DISPERSED FLUORESCENCE SPECTROSCOPY OF RuC: AN EXAMINATION OF THE GROUND AND LOWLYING ELECTRONIC STATES
No full text J.D. Langenberg, R.S. DaBell, L. Shao, D. Dreesen, and M.D. Morse, J. Chem. Phys, 109, 7863 (1998).Author Institution: Department of Chemistry, University of UtahDispersed fluorescence spectroscopy of RuC in a supersonic expansion has allowed for the first observation of the state. This work has also aided in confirming assignments of states from the configuration that were observed . Vibrational progressions were observed in the and states. Derived values for the and states of and , respectively, were also determined
Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases
No full textBACKGROUND: Psoriasis, psoriatic arthritis, spondyloarthritis, rheumatoid arthritis, ulcerative colitis, and Crohn disease share similar underlying pathophysiological processes, providing the opportunity to treat the patients using similar biological therapies. Failure of biological treatments due to underexposure can be managed by therapeutic drug monitoring. Adjusting the treatment based on pharmacokinetic monitoring can be further improved by taking pharmacodynamic parameters such as clinical and molecular markers into account. METHODS: Here, we critically evaluate the existing evidence, the hurdles to be taken, and the opportunities for a widespread implementation of pharmacodynamic monitoring. RESULTS: Pharmacodynamic monitoring typically is the monitoring of biochemical markers. A pharmacodynamic marker preferably is specific for the pharmacological action of a drug, but most of the time nonspecific pharmacodynamic markers are used, such as C-reactive protein and the erythrocyte sedimentation rate. Clinical pharmacodynamic markers typically evaluate physical variables or symptoms. Although physician-reported outcomes have been studied for a longer time and often have been shown to correlate well with molecular pharmacodynamic markers and treatment outcomes, the introduction of mobile health or mHealth technologies caused a shift toward patient-reported outcomes, with the associated challenge to consistently reflect the inflammatory state, thereby preventing undertreatment or unnecessary overdosing of patients. CONCLUSIONS: The primary goal of pharmacodynamic monitoring is to optimize the response, but it can also have an impact on safety, costs, patient adherence, etc. Ideally, the constant remote monitoring of patient-reported disease activity is expected to become the standard, facilitated by mHealth technologies.sponsorship: A. Gils: lecture fees from MSD, Janssen Biologicals, Pfizer, Takeda, Abbvie, Novartis; Advisory board: Takeda; Financial research support: Pfizer, MSD, Takeda; License agreement: R-biopharm, apDia, Merck. The remaining author declares no conflict of interest. (Pfizer, MSD, Takeda)status: Publishe
